Home »
RESILIENT was a single arm, open label, phase II/III study to test if label agnostic therapy regimens guided by Encyclopedic Tumor Analysis can offer meaningful clinical benefit for patients with relapsed refractory metastatic malignancies. Patients with advanced refractory solid organ malignancies where disease had progressed following 2 lines of systemic treatments were enrolled in the […]
When Marleen Kemper was a child, she watched two of her primary-school classmates get ill. One had a brain tumor, and the other contracted an infection in his gut. Both of them died. Kemper was around ten at the time, and knew that she didn’t want to see another friend perish. She told her parents […]
Patients who first saw a physical therapist or chiropractor for low back pain, rather than a primary care physician, were much less likely to be prescribed opioids. Low back pain is one of the most common conditions Americans seek care for—and one of the more common reasons for an opioid prescription. Facing the opioid crisis, […]
Scientists at the University of Birmingham have found an anti-malarial drug was effective in treating head and neck cancer in mice. The drug quinacrine was used extensively to prevent and treat malaria in soldiers fighting in mosquito-ridden areas during World War Two. It is similar to the quinine that makes tonic water glow, has minimal […]
Since its discovery in 1954, there have been almost no recorded cases of tuberculosis becoming resistant to the antibiotic drug D-cycloserine (DCS) in patients. With resistance to many other drugs on the rise, a team of Crick researchers set out to find out why DCS has evaded resistance for so long. In a new study, […]
An interdisciplinary study led by Professor Daniel Wiesen from the University of Cologne’s Department of Business Administration and Health Care Management showed that expert feedback leads to more appropriate antibiotic therapy decisions. A central result of the study is that physicians in an early stage of their career especially benefit from expert feedback. The study, […]
In a new register-based study, Swedish and Danish researchers show that common drugs for Inflammatory Bowel Disease (IBD), so called TNF-α inhibitors, are not linked to increased risk of serious infections in children. Previous studies have shown an increased risk in corresponding adult patients. The results are published in The Lancet Gastroenterology & Hepatology. “Together […]
(HealthDay)—Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) is associated with increased risks for pancreatitis and pancreatic cancer in patients with newly diagnosed type 2 diabetes, according to a study published online Aug. 20 in Diabetes Care. Minyoung Lee, M.D., from the Yonsei University College of Medicine in Seoul, South Korea, and colleagues used the Korean National […]
(HealthDay)—Using buprenorphine to treat opioid use disorder (OUD) may increase adherence to treatments for other chronic conditions, according to a study published in the September issue of Medical Care. Hsien-Yen Chang, Ph.D., from Johns Hopkins University in Baltimore, and colleagues used Truven Health’s MarketScan data to identify 12,719 commercially insured individuals with a diagnosis of […]
The maker of the powerful painkiller OxyContin has agreed to provide access to propriety research and other data to researchers at Oklahoma State University to help them find causes and treatments for drug addiction. Stamford, Connecticut-based Purdue Pharma announced the agreement Thursday in a joint statement with the university. Purdue said it will provide Oklahoma […]